Xcovery LLC Presents at EBD Group's 7th Annual BIO-Europe Spring Conference 2013, Mar-12-2013 11:30 AM. Venue: Centre Covencions International Barcelona, Plaça de Willy Brandt, 11-14, 08019 Barcelona, Spain.

Xcovery LLC Presents at Windhover's Therapeutic Area Partnerships Conference, Nov-29-2012 04:40 PM. Venue: Westin Copley Place, Boston, Massachusetts, United States.

Xcovery LLC announced that it will begin its Phase I/II clinical trial of its oral angiogenesis inhibitor, X-82, for the treatment of neovascular 'wet' age-related macular degeneration (AMD). The initial Phase I/II trial will assess the preliminary safety and tolerability of X-82, a unique tyrosine kinase inhibitor (TKI) in an oral formulation that acts by blocking pathologic blood vessel growth. The trial will enroll a maximum of 20 patients and will be conducted at three ophthalmology centers in the US. X-82 inhibits both vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF), two important targets implicated in wet AMD. The compound has been designed to have a favorable toxicity profile and better tolerability as an oral medication than previous injectable drugs in this class.